celgene_1_02

Celgene’s Otezla approved for NHS use

pharmafile | August 3, 2016 | News story | Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast 

NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of patients suffering from severe psoriasis.  

This decision comes after the organisation previously rejected the drug last year in November. It also came up against resistance from Germany’s cost-effectiveness agency IQWIG last year when it demanded more data to prove that the drug is worth its cost.

After conducting a rapid review in response to a patient access scheme submitted by Celgene, NICE is now recommending the drug as a treatment for severe chronic plaque psoriasis that has not responded to systemic therapy, or systemic therapy is contradicted or not tolerated, on the condition that the company provides it to the NHS at the discounted rate agreed to in the scheme

Analysts predict Otezla will achieve $1.3 billion in sales by 2018. Celgene’s expectations are even more ambitious; through exploring other possible applications for the drug such as rheumatoid arthritis treatment, the company anticipates up to $2 billion peak sales.

Matt Fellows

Related Content

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of …

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended …

Latest content